File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Renal herb formula protects against hyperuricemic nephropathy by inhibiting apoptosis and inflammation

TitleRenal herb formula protects against hyperuricemic nephropathy by inhibiting apoptosis and inflammation
Authors
KeywordsGout
Hyperuricemia
Hyperuricemic nephropathy
Monosodium urate crystal
Potassium oxonate
Uric acid
Issue Date9-May-2023
PublisherElsevier
Citation
Phytomedicine, 2023, v. 116 How to Cite?
Abstract

Background: Hyperuricemic nephropathy may be induced by the elevation and accumulation of uric acid in kidney after hyperuricemia, which leads to kidney residential cells apoptosis and inflammation. Renal herb formula (RHF) is a self-designed formula based on traditional Chinese medicine theory and clinical practice in kidney disease treatment. In the literature available currently, there is not yet research article reporting the renoprotective effect of RHF against hyperuricemic nephropathy.Purpose: This study was performed to analyze the bioactive compound profiles of RHF, evaluate its protective effects against hyperuricemic nephropathy, and investigate the mechanisms of actions regarding apoptosis and inflammation.Methods: Ultra-performance liquid chromatography with a diode-array detector was applied to establish fingerprint and chemical composition of RHF. Potassium oxonate was used to induce hyperuricemic nephropathy in mice, and uric acid was used to stimulate apoptosis and inflammatory response in HK-2 cells, while the mice and cells were treated with RHF to explore its reno-protective effects and mechanisms.Results: It was found that chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, and isochlorogenic acid A-C may be the characteristic components of RHF. RHF treatment could improve kidney functions in mice with hyperuricemic nephropathies, such as decreasing urine protein, uric acid, and creatinine and serum uric acid, creatinine, and urea nitrogen. Histopathological observations showed that RHF treatment ameliorated kidney glomerular hypotrophy, tubular damage, and inflammatory infiltration. Mechanism studies revealed that RHF inhibited kidney residential cell apoptosis and inflammatory response by targeting the p53-associated intrinsic apoptosis pathway and NF-kappa B-mediated inflammatory pathway.Conclusion: Taken together, it could be concluded that RHF exerted reno-protective effects against hyperuricemic nephropathy through reducing apoptosis and inflammation. RHF and the bioactive compounds chlorogenic acid analogs as promising candidates may be developed into novel and effective drugs for hyperuricemic nephropathy treatment and management.


Persistent Identifierhttp://hdl.handle.net/10722/340051
ISSN
2023 Impact Factor: 6.7
2023 SCImago Journal Rankings: 1.267
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTang, GY-
dc.contributor.authorLi, S-
dc.contributor.authorXu, Y-
dc.contributor.authorZhang, C-
dc.contributor.authorXu, XY-
dc.contributor.authorXu, L-
dc.contributor.authorWang, N-
dc.contributor.authorFeng, YB-
dc.date.accessioned2024-03-11T10:41:18Z-
dc.date.available2024-03-11T10:41:18Z-
dc.date.issued2023-05-09-
dc.identifier.citationPhytomedicine, 2023, v. 116-
dc.identifier.issn0944-7113-
dc.identifier.urihttp://hdl.handle.net/10722/340051-
dc.description.abstract<p>Background: Hyperuricemic nephropathy may be induced by the elevation and accumulation of uric acid in kidney after hyperuricemia, which leads to kidney residential cells apoptosis and inflammation. Renal herb formula (RHF) is a self-designed formula based on traditional Chinese medicine theory and clinical practice in kidney disease treatment. In the literature available currently, there is not yet research article reporting the renoprotective effect of RHF against hyperuricemic nephropathy.Purpose: This study was performed to analyze the bioactive compound profiles of RHF, evaluate its protective effects against hyperuricemic nephropathy, and investigate the mechanisms of actions regarding apoptosis and inflammation.Methods: Ultra-performance liquid chromatography with a diode-array detector was applied to establish fingerprint and chemical composition of RHF. Potassium oxonate was used to induce hyperuricemic nephropathy in mice, and uric acid was used to stimulate apoptosis and inflammatory response in HK-2 cells, while the mice and cells were treated with RHF to explore its reno-protective effects and mechanisms.Results: It was found that chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, and isochlorogenic acid A-C may be the characteristic components of RHF. RHF treatment could improve kidney functions in mice with hyperuricemic nephropathies, such as decreasing urine protein, uric acid, and creatinine and serum uric acid, creatinine, and urea nitrogen. Histopathological observations showed that RHF treatment ameliorated kidney glomerular hypotrophy, tubular damage, and inflammatory infiltration. Mechanism studies revealed that RHF inhibited kidney residential cell apoptosis and inflammatory response by targeting the p53-associated intrinsic apoptosis pathway and NF-kappa B-mediated inflammatory pathway.Conclusion: Taken together, it could be concluded that RHF exerted reno-protective effects against hyperuricemic nephropathy through reducing apoptosis and inflammation. RHF and the bioactive compounds chlorogenic acid analogs as promising candidates may be developed into novel and effective drugs for hyperuricemic nephropathy treatment and management.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofPhytomedicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectGout-
dc.subjectHyperuricemia-
dc.subjectHyperuricemic nephropathy-
dc.subjectMonosodium urate crystal-
dc.subjectPotassium oxonate-
dc.subjectUric acid-
dc.titleRenal herb formula protects against hyperuricemic nephropathy by inhibiting apoptosis and inflammation-
dc.typeArticle-
dc.identifier.doi10.1016/j.phymed.2023.154812-
dc.identifier.pmid37167821-
dc.identifier.scopuseid_2-s2.0-85157985708-
dc.identifier.volume116-
dc.identifier.isiWOS:001004542300001-
dc.publisher.placeMUNICH-
dc.identifier.issnl0944-7113-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats